A detailed history of Eaton Vance Management transactions in Horizon Therapeutics Public LTD CO stock. As of the latest transaction made, Eaton Vance Management holds 87,352 shares of HZNP stock, worth $0. This represents 0.01% of its overall portfolio holdings.

Number of Shares
87,352
Previous 86,696 0.76%
Holding current value
$0
Previous $6.92 Million 21.81%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$58.92 - $84.67 $38,651 - $55,543
656 Added 0.76%
87,352 $5.41 Million
Q2 2022

Aug 15, 2022

SELL
$79.4 - $116.36 $415,023 - $608,213
-5,227 Reduced 5.69%
86,696 $6.92 Million
Q1 2022

May 16, 2022

BUY
$86.42 - $109.81 $4.74 Million - $6.02 Million
54,813 Added 147.7%
91,923 $9.67 Million
Q4 2021

Feb 14, 2022

SELL
$98.56 - $119.91 $58,150 - $70,746
-590 Reduced 1.56%
37,110 $3.99 Million
Q3 2021

Nov 15, 2021

BUY
$91.91 - $110.37 $64,337 - $77,259
700 Added 1.89%
37,700 $4.05 Million
Q2 2021

Aug 16, 2021

BUY
$86.24 - $95.92 $719,500 - $800,260
8,343 Added 29.11%
37,000 $3.47 Million
Q1 2021

May 17, 2021

BUY
$71.83 - $95.48 $107,314 - $142,647
1,494 Added 5.5%
28,657 $2.64 Million
Q4 2020

Feb 12, 2021

BUY
$67.0 - $84.39 $1,005 - $1,265
15 Added 0.06%
27,163 $1.99 Million
Q2 2020

Aug 13, 2020

SELL
$30.2 - $56.98 $8,154 - $15,384
-270 Reduced 0.98%
27,148 $1.51 Million
Q1 2020

May 14, 2020

BUY
$24.87 - $38.56 $4,949 - $7,673
199 Added 0.73%
27,418 $812,000
Q4 2019

Feb 11, 2020

BUY
$25.43 - $36.67 $2,746 - $3,960
108 Added 0.4%
27,219 $985,000
Q3 2019

Nov 14, 2019

BUY
$23.0 - $27.97 $2,553 - $3,104
111 Added 0.41%
27,111 $738,000
Q2 2019

Aug 16, 2019

BUY
$22.81 - $28.48 $615,870 - $768,960
27,000 New
27,000 $650,000

Others Institutions Holding HZNP

About Horizon Therapeutics Public Ltd Co


  • Ticker HZNP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 230,384,000
  • Description
  • Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...
More about HZNP
Track This Portfolio

Track Eaton Vance Management Portfolio

Follow Eaton Vance Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.